Salvianolic acid A for injection is under clinical development by Shanghai Pharmaceutical Group and currently in Phase I for Angina (Angina Pectoris). According to GlobalData, Phase I drugs for Angina (Angina Pectoris) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Salvianolic acid A for injection’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Salvianolic acid A for injection overview
Small molecule is under development for the treatment of angina pectoris of coronary heart disease. The drug candidate constitutes salvianolic acid A and it is administered through intravenous route.
The drug candidate was under development for the treatment of acute coronary syndrome.
Shanghai Pharmaceutical Group overview
Shanghai Pharmaceutical (Group) Co., Ltd (SPGCL) is a pharmaceuticals and healthcare service provider, based in China. The company’s products portfolio includes active pharmaceutical ingredients, alexipharmic, alimentary tract and metabolism, anaesthetic, anti-allergic drugs, medicines: antibiotics, prescription drugs, traditional Chinese medicines and over the counter drugs. It markets its drugs in 30 countries from five foreign offices. The company’s research and development facility, central research institute, operates 10 centers across China. It operates as a subsidiary of Shanghai Industrial Investment (Holdings) Co. Ltd. SPGCL is headquartered in Shanghai, China.
For a complete picture of Salvianolic acid A for injection’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
